Release forms - oral solution (vials) 0.1% - 10 ml
Pharmacotherapeutic group - m-holinoblokator
Pharmacological action
bronchodilatory
antiarrhythmic
m-anticholinergic
antiulcer
spasmolytic
Ingredients - atropine 0.1%
Statement
Gastrojejunal ulcer
Pain in the abdomen and pelvis
Pain, localized in the upper abdomen
Pain associated with urination
Diseases of the eye and adnexa
Diseases of vocal cords and larynx, not elsewhere classified
Diseases of the gallbladder, biliary tract and pancreas
Disease of salivary glands
Painful urination, unspecified
Anomalies of the pupil function
Asthma
Asthma, unspecified
Asthma with a predominance of allergic component
Secondary parkinsonism
Bile duct stones without cholangitis or cholecystitis
Bile duct stones with cholangitis
Stones of the bile duct with cholecystitis
Iridocyclitis
Cholinesterase inhibitors
Keratitis
Keratoconjunctivitis
Accommodation disturbances
Violations of refraction and accommodation
Violations of the secretion of salivary glands
Atrioventricular block second degree
Atrioventricular block full
Atrioventricular block first degree
Atrio-ventricular (atrioventricular) block and left bundle (Gisa)
Occlusion of retinal vessels
Pilorospazme, not elsewhere classified
Unspecified renal colic
Acute bronchiolitis
Acute pancreatitis
Acute cholecystitis
Poisoning by drugs, medicaments and biological substances
Poisoning by drugs acting primarily on the autonomic nervous system
Non-allergic asthma
Peptic ulcer unspecified location
Symptoms and signs involving the urinary system
Symptoms and signs involving the digestive system and abdomen
Anchone
Mixed asthma
Injuries to the eye and orbit
Injury, poisoning and certain other consequences of external causes
Chronic pancreatitis of alcoholic etiology
Chronic cholecystitis
Chorioretinal inflammation
Chorioretinal inflammation, unspecified
Cholecystitis
Cholecystitis, unspecified
Other and unspecified atrioventricular block
Other parasimpatomimeticheskimi (cholinergic) means
Other diseases of the eye and adnexa
Other diseases of the pancreas
Other diseases of stomach and duodenum
Other retinal artery occlusion
Other and unspecified abdominal pain
Other superficial keratitis without conjunctivitis
Other chronic pancreatitis
Other forms of cholelithiasis
Other forms of cholecystitis
Cholelithiasis
Helcoma
Duodenal ulcer
Gastric ulcer
The composition of the components
atropine
Description
White crystalline or granular powder, soluble in water and alcohol.
Pharmacodynamics
Alkaloid contained in the plant family Solanaceae, m-cholinergic receptor blocker. Prevents the stimulating action of acetylcholine, reduces the secretion of salivary, gastric, bronchial, lacrimal, sweat glands, pancreas. Reduces muscle tone in the gastrointestinal tract, bile duct and gallbladder, causing tachycardia, improves AV conduction. After iv administration the maximal effect occurs within 2-4 minutes after oral administration (as drops) after 30 minutes. Stimulates the cerebral cortex (in high doses). Extends pupils, difficult outflow of intraocular fluid, intraocular pressure increases, causing paralysis of accommodation. Pupil, advanced atropine, not narrowed at instillation cholinomimetic drugs. Maximal mydriasis occurs within 30-40 min, disappears after 7-10 days.
Pharmacokinetics
Relationship to plasma proteins - 18%. Passes through the BBB. Excreted by the kidneys (50% unchanged).
Application
Gastric ulcer and duodenal ulcer, pilorospazme, cholelithiasis, cholecystitis, acute pancreatitis, hypersalivation (parkinsonism, poisoning with heavy metal salts), intestinal spasms and urinary tract, liver and renal colic, asthma, to prevent broncho-and laryngospasm, AV block , m-poisoning holinomimetikami (fly agaric), anticholinesterases, premedication before surgery. Locally (in Ophthalmology): to study the retina, to improve pupil achievement and paralysis of accommodation in order to determine the true refractive error, for the treatment of iritis, iridocyclitis, horioiditov, keratitis, embolism and central retinal artery spasm, and some eye injuries.
Dosing regimen
N / k / m or / by 0.25-1 mg 1-2 times a day. In ophthalmology: instill 1-2 drops of 1% solution (for children use a solution of lesser concentration) in a patient eye, the multiplicity of applications - up to 3 times at intervals of 6.5 h. In some cases, 0.1% solution was injected subkonyunktivalno 0.2-0.5 ml or parabulbarno - 0.3-0.5 ml. By electrophoresis through the eyelids or eye bath is administered 0.5% solution.
Side Effects
Dry mouth, mydriasis, bowel atony, dizziness, tachycardia, difficulty urinating, flushing of skin of eyelid, photophobia, conjunctival edema of eyelids and eyeball. Xerostomia, mydriasis, cycloplegia, tachycardia, intestinal atony, atonia of the bladder, headache, dizziness, loss of touch.
Contraindications
Hypersensitivity, angle-closure glaucoma, urination disorders in the prostate gland adenoma.
Cautions
With instillation of the solution in the eye to press the lower lacrimal point in order to avoid getting the solution in the nasopharynx. When subconjunctival or parabulbarno Introduction to reduce tachycardia advisable to appoint validol.
Pharmacotherapeutic group - m-holinoblokator
Pharmacological action
bronchodilatory
antiarrhythmic
m-anticholinergic
antiulcer
spasmolytic
Ingredients - atropine 0.1%
Statement
Gastrojejunal ulcer
Pain in the abdomen and pelvis
Pain, localized in the upper abdomen
Pain associated with urination
Diseases of the eye and adnexa
Diseases of vocal cords and larynx, not elsewhere classified
Diseases of the gallbladder, biliary tract and pancreas
Disease of salivary glands
Painful urination, unspecified
Anomalies of the pupil function
Asthma
Asthma, unspecified
Asthma with a predominance of allergic component
Secondary parkinsonism
Bile duct stones without cholangitis or cholecystitis
Bile duct stones with cholangitis
Stones of the bile duct with cholecystitis
Iridocyclitis
Cholinesterase inhibitors
Keratitis
Keratoconjunctivitis
Accommodation disturbances
Violations of refraction and accommodation
Violations of the secretion of salivary glands
Atrioventricular block second degree
Atrioventricular block full
Atrioventricular block first degree
Atrio-ventricular (atrioventricular) block and left bundle (Gisa)
Occlusion of retinal vessels
Pilorospazme, not elsewhere classified
Unspecified renal colic
Acute bronchiolitis
Acute pancreatitis
Acute cholecystitis
Poisoning by drugs, medicaments and biological substances
Poisoning by drugs acting primarily on the autonomic nervous system
Non-allergic asthma
Peptic ulcer unspecified location
Symptoms and signs involving the urinary system
Symptoms and signs involving the digestive system and abdomen
Anchone
Mixed asthma
Injuries to the eye and orbit
Injury, poisoning and certain other consequences of external causes
Chronic pancreatitis of alcoholic etiology
Chronic cholecystitis
Chorioretinal inflammation
Chorioretinal inflammation, unspecified
Cholecystitis
Cholecystitis, unspecified
Other and unspecified atrioventricular block
Other parasimpatomimeticheskimi (cholinergic) means
Other diseases of the eye and adnexa
Other diseases of the pancreas
Other diseases of stomach and duodenum
Other retinal artery occlusion
Other and unspecified abdominal pain
Other superficial keratitis without conjunctivitis
Other chronic pancreatitis
Other forms of cholelithiasis
Other forms of cholecystitis
Cholelithiasis
Helcoma
Duodenal ulcer
Gastric ulcer
The composition of the components
atropine
Description
White crystalline or granular powder, soluble in water and alcohol.
Pharmacodynamics
Alkaloid contained in the plant family Solanaceae, m-cholinergic receptor blocker. Prevents the stimulating action of acetylcholine, reduces the secretion of salivary, gastric, bronchial, lacrimal, sweat glands, pancreas. Reduces muscle tone in the gastrointestinal tract, bile duct and gallbladder, causing tachycardia, improves AV conduction. After iv administration the maximal effect occurs within 2-4 minutes after oral administration (as drops) after 30 minutes. Stimulates the cerebral cortex (in high doses). Extends pupils, difficult outflow of intraocular fluid, intraocular pressure increases, causing paralysis of accommodation. Pupil, advanced atropine, not narrowed at instillation cholinomimetic drugs. Maximal mydriasis occurs within 30-40 min, disappears after 7-10 days.
Pharmacokinetics
Relationship to plasma proteins - 18%. Passes through the BBB. Excreted by the kidneys (50% unchanged).
Application
Gastric ulcer and duodenal ulcer, pilorospazme, cholelithiasis, cholecystitis, acute pancreatitis, hypersalivation (parkinsonism, poisoning with heavy metal salts), intestinal spasms and urinary tract, liver and renal colic, asthma, to prevent broncho-and laryngospasm, AV block , m-poisoning holinomimetikami (fly agaric), anticholinesterases, premedication before surgery. Locally (in Ophthalmology): to study the retina, to improve pupil achievement and paralysis of accommodation in order to determine the true refractive error, for the treatment of iritis, iridocyclitis, horioiditov, keratitis, embolism and central retinal artery spasm, and some eye injuries.
Dosing regimen
N / k / m or / by 0.25-1 mg 1-2 times a day. In ophthalmology: instill 1-2 drops of 1% solution (for children use a solution of lesser concentration) in a patient eye, the multiplicity of applications - up to 3 times at intervals of 6.5 h. In some cases, 0.1% solution was injected subkonyunktivalno 0.2-0.5 ml or parabulbarno - 0.3-0.5 ml. By electrophoresis through the eyelids or eye bath is administered 0.5% solution.
Side Effects
Dry mouth, mydriasis, bowel atony, dizziness, tachycardia, difficulty urinating, flushing of skin of eyelid, photophobia, conjunctival edema of eyelids and eyeball. Xerostomia, mydriasis, cycloplegia, tachycardia, intestinal atony, atonia of the bladder, headache, dizziness, loss of touch.
Contraindications
Hypersensitivity, angle-closure glaucoma, urination disorders in the prostate gland adenoma.
Cautions
With instillation of the solution in the eye to press the lower lacrimal point in order to avoid getting the solution in the nasopharynx. When subconjunctival or parabulbarno Introduction to reduce tachycardia advisable to appoint validol.
No comments:
Post a Comment